Moderna, Inc. (MRNA) Shareholder/Analyst Call Transcript

Core Insights - The company is excited to share new data on asset 4359, which is becoming a late-stage asset similar to INT [1] - The presentation includes discussions on melanoma and the data related to 4359, featuring experts in the field [1] Pipeline Overview - The company utilizes mRNA technology in various innovative ways, including personalized therapies through the Intismeran autogene program [2] - Off-the-shelf therapies are being developed, referred to as cancer antigen therapies (CATs), along with a T-cell engager program [2] - The company is also advancing in vivo cell therapy programs, which are expected to enhance cell therapy applications [2] Efficacy Potential - The company believes that its programs hold the promise of potential efficacy across a wide range of indications and different therapeutic areas [3]